Literature DB >> 32398764

Psilocybin: from ancient magic to modern medicine.

David E Nichols1.   

Abstract

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is an indole-based secondary metabolite produced by numerous species of mushrooms. South American Aztec Indians referred to them as teonanacatl, meaning "god's flesh," and they were used in religious and healing rituals. Spanish missionaries in the 1500s attempted to destroy all records and evidence of the use of these mushrooms. Nevertheless, a 16th century Spanish Franciscan friar and historian mentioned teonanacatl in his extensive writings, intriguing 20th century ethnopharmacologists and leading to a decades-long search for the identity of teonanacatl. Their search ultimately led to a 1957 photo-essay in a popular magazine, describing for the Western world the use of these mushrooms. Specimens were ultimately obtained, and their active principle identified and chemically synthesized. In the past 10-15 years several FDA-approved clinical studies have indicated potential medical value for psilocybin-assisted psychotherapy in treating depression, anxiety, and certain addictions. At present, assuming that the early clinical studies can be validated by larger studies, psilocybin is poised to make a significant impact on treatments available to psychiatric medicine.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32398764     DOI: 10.1038/s41429-020-0311-8

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  17 in total

1.  Optimization through a Box-Behnken Experimental Design of the Microwave-Assisted Extraction of the Psychoactive Compounds in Hallucinogenic Fungi (Psylocibe cubensis).

Authors:  Curro Polo-Castellano; José Á Álvarez; Miguel Palma; Gerardo F Barbero; Jesús Ayuso; Marta Ferreiro-González
Journal:  J Fungi (Basel)       Date:  2022-06-02

Review 2.  Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.

Authors:  Aryan Sarparast; Kelan Thomas; Benjamin Malcolm; Christopher S Stauffer
Journal:  Psychopharmacology (Berl)       Date:  2022-03-07       Impact factor: 4.415

Review 3.  Evolutionary Morphogenesis of Sexual Fruiting Bodies in Basidiomycota: Toward a New Evo-Devo Synthesis.

Authors:  Máté Virágh; Zsolt Merényi; Árpád Csernetics; Csenge Földi; Neha Sahu; Xiao-Bin Liu; David S Hibbett; László G Nagy
Journal:  Microbiol Mol Biol Rev       Date:  2021-11-24       Impact factor: 13.044

4.  Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity.

Authors:  Joyce Huang; Michelle Pham; William J Panenka; William G Honer; Alasdair M Barr
Journal:  Front Psychiatry       Date:  2022-05-18       Impact factor: 5.435

Review 5.  Biosynthesis and synthetic biology of psychoactive natural products.

Authors:  Cooper S Jamieson; Joshua Misa; Yi Tang; John M Billingsley
Journal:  Chem Soc Rev       Date:  2021-06-21       Impact factor: 60.615

6.  Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples.

Authors:  Alexander M Sherwood; Robert B Kargbo; Kristi W Kaylo; Nicholas V Cozzi; Poncho Meisenheimer; James A Kaduk
Journal:  Acta Crystallogr C Struct Chem       Date:  2022-01-01       Impact factor: 1.172

7.  Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems.

Authors:  Elena Argento; Devon Christie; Lindsay Mackay; Cody Callon; Zach Walsh
Journal:  Front Psychiatry       Date:  2021-09-06       Impact factor: 4.157

Review 8.  Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Justin Grant; Amza Ali; Lorenzo Gordon; Wilfred Ngwa
Journal:  Molecules       Date:  2022-04-14       Impact factor: 4.927

Review 9.  The Therapeutic Potential of Psilocybin.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Henkel Valentine; Justin Grant; Amza Ali; Wilfred Ngwa; Lorenzo Gordon
Journal:  Molecules       Date:  2021-05-15       Impact factor: 4.411

Review 10.  Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy.

Authors:  Sascha B Thal; Stephen J Bright; Jason M Sharbanee; Tobias Wenge; Petra M Skeffington
Journal:  Front Psychol       Date:  2021-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.